Browsing by Author Fulcher, Greg

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 57  next >
Issue DateTitleAuthor(s)Citation
2012Activated protein C inhibits pancreatic islet inflammation, stimulates T regulatory cells, and prevents diabetes in non-obese diabetic (NOD) miceDervish, Suat; Fulcher, Greg; Jackson, Christopher; Xue, Meilang; Harrison, Leonard; Northern Clinical School: Kolling Institute; Northern Clinical School: Medicine; Northern Clinical School: Medicine; Northern Clinical School: MedicineActivated protein C inhibits pancreatic islet inflammation, stimulates T regulatory cells, and prevents diabetes in non-obese diabetic (NOD) mice, Journal of Biological Chemistry, vol.287, 20, 2012,pp 16356-16364
2005ADVANCE - Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline.Adams, Mark; Chalmers, John; Cooper, Michael; Fulcher, Greg; MacMahon, Stephen; Mitchell, Ronald (Paul); Neal, Bruce; Patel, Anushka; Pollock, Carol; Watson, John; Woodward, Mark; et, al; Ferrannini, E; Glasziou, Paul P; Grobbee, Diederick E.; Hamet, P; Harrap, S; Heller, S; Liu, L; Mancia, Giuseppe; Marre, M; Central Clinical School: Medicine; The George Institute for International Health; Central Clinical School: Obstetrics & Gynaecology; Northern Clinical School: Medicine; The George Institute for International Health; Western Clinical School: Westmead Millennium Institute; The George Institute for International Health; The George Institute for International Health; Northern Clinical School: Medicine; School of Medical Sciences: Biomedical Sciences; The George Institute for International HealthADVANCE - Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline., Diabetic Medicine: 2005 Diabetes UK, vol.22,(7),2005,pp 882-888
2017The association between patient activation and self-care practices: A cross-sectional study of an Australian population with comorbid diabetes and chronic kidney diseaseUsherwood, Timothy; Fulcher, Greg; Johnson, Greg; Kerr, Peter G; Lo, Clement; Polkinghorne, Kevan; Ranasinha, Sanjeeva; Teede, Helena J; Walker, Rowan G; Zimbudzi, Edward; Zoungas, Sophia; Westmead Clinical School: General PracticeThe association between patient activation and self-care practices: A cross-sectional study of an Australian population with comorbid diabetes and chronic kidney disease, Health Expectations, vol.20, 6, 2017,pp 1375-1384
2012Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholdsChalmers, John; Colagiuri, Stephen; Fulcher, Greg; Neal, Bruce; Patel, Anushka; Woodward, Mark; Cooper, M; de Galan, B; Hamet, Pavel; Harrap, Stephen B.; Heller, Simon; Li, Q; MacMahon, Stephen; Marre, Michel; Ninomiya, T; Poulter, Neil; Travert, F; Zoungas, Sophia; The George Institute for Global Health; Central Clinical School: Medicine; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global HealthAssociation of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds, Diabetologia: clinical and experimental diabetes and metabolism, vol.55, 3, 2012,pp 636-643
2016Bone Mineral Density in Postmenopausal Women Heterozygous for the C282Y HFE MutationClifton-Bligh, Phillip; Fulcher, Greg; Gunton, Jenny Elizabeth; Gates, Frances; Northern Clinical School: Medicine; Northern Clinical School: Medicine; Western Clinical School: Westmead Institute for Medical ResBone Mineral Density in Postmenopausal Women Heterozygous for the C282Y HFE Mutation, Journal of Osteoporosis, vol.2016, N/A, 2016,pp 1-6
2017Canagliflozin and cardiovascular and renal events in type 2 diabetesFulcher, Greg; Neal, Bruce; Perkovic, Vlado; de Zeeuw, Dick; Desai, Mehul; Erondu, N; Law, Gordon; Mahaffey, Kenneth W; Matthews, David; Shaw, Wayne; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthCanagliflozin and cardiovascular and renal events in type 2 diabetes, New England Journal of Medicine, vol.377, 7, 2017,pp 644-657
2018Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)Neal, Bruce; Perkovic, Vlado; Barrett, Terrance D; de Zeeuw, Dick; Desai, Mehul; Figtree, Gemma; Fulcher, Greg; Mahaffey, Kenneth W; Matthews, David. R.; Radholm, Karin; Shaw, Wayne; Solomon, Scott; The George Institute for Global HealthCanagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study), Circulation, vol.138, 5, 2018,pp 458-468
2018Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)Neal, Bruce; Perkovic, Vlado; Barrett, Terrance D; de Zeeuw, Dick; Desai, Mehul; Figtree, Gemma; Fulcher, Greg; Mahaffey, Kenneth W; Matthews, David. R.; Radholm, Karin; Shaw, Wayne; Solomon, Scott; The George Institute for Global HealthCanagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study), Circulation, vol.138, 5, 2018,pp 458-468
2015Central Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and NeuroprotectionFulcher, Greg; Glastras, Sarah; Hocking, Samantha; Krause, Martin; McGrath, Rachael; Tjoeng, Iona; Northern Clinical School: Medicine; Children's Hospital Westmead: Childrens Medical Research Ins; Northern Clinical School: Medicine; Nepean Clinical School: Medicine; Northern Clinical School: MedicineCentral Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and Neuroprotection, Journal of Steroids & Hormonal Science, vol.6, 1, 2015,pp 1-8
2017Changes in bone mineral density related to changes in serum 25-OH vitamin D concentrations over a two-year period in postmenopausal womenBaber, Rodney; Clifton-Bligh, Phillip; Clifton-Bligh, Roderick; Fulcher, Greg; Nery, Maria Liza; Northern Clinical School: Obstetrics & Gynaecology; Northern Clinical School: Medicine; Northern Clinical School: Medicine; Northern Clinical School: MedicineChanges in bone mineral density related to changes in serum 25-OH vitamin D concentrations over a two-year period in postmenopausal women, Endocrine, vol.58, 3, 2017,pp 587-590
2016Clinical use of the co-formulation of insulin degludec and insulin aspartFulcher, Greg; Arechavaleta, R.; Awata, T.; Bain, S. C.; Ceriello, A; et al, .; Gonzalez-Galvez, G.; Hirose, T.; Kumar, A.; Unnikrishnan, Ambika Gopalakrishnan; Northern Clinical School: MedicineClinical use of the co-formulation of insulin degludec and insulin aspart, International Journal of Clinical Practice, vol.70, 8, 2016,pp 657-667
2016Clinical use of the co-formulation of insulin degludec and insulin aspartFulcher, Greg; Arechavaleta, R.; Awata, T.; Bain, S. C.; Ceriello, A; et al, .; Gonzalez-Galvez, G.; Hirose, T.; Kumar, A.; Unnikrishnan, Ambika Gopalakrishnan; Northern Clinical School: MedicineClinical use of the co-formulation of insulin degludec and insulin aspart, International Journal of Clinical Practice, vol.70, 8, 2016,pp 657-667
2014Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: A phase 3a, randomized, treat-to-target trialFulcher, Greg; Andersen, Thomas; Bantwal, Ganapathi; Christiansen, J S; Mersebach, Henriette; Niskanen, Leo; Polaszewska-Muszynska, Miroslawa; Northern Clinical School: MedicineComparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: A phase 3a, randomized, treat-to-target trial, Diabetes Care, vol.37, 8, 2014,pp 2084-2090
2008Drug-induced thyroiditis and papillary carcinoma in a minocycline-pigmented black thyroid glandFulcher, Greg; Gill, Anthony; Sywak, Mark; Alvarado, Raul; Tacon, Lyndal; Tan, Charles; Northern Clinical School: Medicine; Deans Unit: (CIPHER); Northern Clinical School: SurgeryDrug-induced thyroiditis and papillary carcinoma in a minocycline-pigmented black thyroid gland, Thyroid, vol.18,(7),2008,pp 795-797
2010Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular EventsFulcher, Greg; Belenkov, Yuri; Bethel, M. Angelyn; Boolell, Mitradev; Buckley, Brendan M.; Buse, John B.; Chacra, Antonio R.; et al, various; Haffner, Steven; Holman, Rury R.; Holzhauer, Björn; Hua, Tsushung A.; McMurray, John J.V.; Northern Clinical School: MedicineEffect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events, New England Journal of Medicine, vol.362, 16,pp 1463-1476
2010Effect of Valsartan on the Incidence of Diabetes and Cardiovascular EventsFulcher, Greg; Belenkov, Yuri; Bethel, M. Angelyn; Boolell, Mitradev; Buckley, Brendan M.; Buse, John B.; Chacra, Antonio R.; et al, various; Haffner, Steven; Holman, Rury R.; Holzhauer, Björn; Hua, Tsushung A.; McMurray, John J.V.; Northern Clinical School: MedicineEffect of Valsartan on the Incidence of Diabetes and Cardiovascular Events, New England Journal of Medicine, vol.362, 16,pp 1477-1490
2009The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study.Fulcher, Greg; Keech, Anthony (Tony); Pardy, Christopher; Tse, D; D'Emden, Michael C.; Ehnholm, Christian; FIELD study investigators, Fenofibrate Intervention and Event Lowering in Diabetes; O'Brien, Richard; Scott, Russell; Taskinen, M.; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreThe effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study., Diabetes Care, vol.32,(3),2009,pp 493-498
2017Effects of sotagliflozin added to insulin in patients with type 1 diabetesFulcher, Greg; Banks, Phillip; Buse, John B.; Danne, Thomas; Davies, Melanie; Garg, Satish K.; Gesty-Palmer, Diane; Henry, Robert R.; Kushner, Jake A.; Lapuerta, Pablo; Mcguire, Darren K; Peters, Anne; Pozzilli, Paolo; Simo, Raphael; Strumph, Paul; Northern Clinical School: MedicineEffects of sotagliflozin added to insulin in patients with type 1 diabetes, New England Journal of Medicine, vol.377, 24, 2017,pp 2337-2348
2013Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trialAdams, Mark; Anderson, Craig; Arima, Hisatomi; Chalmers, John; Fulcher, Greg; Hata, Jun; Joshi, Rohina; Kengne, Andre; Neal, Bruce; Ninomiya, Toshiharu; Patel, Anushka; Pollock, Carol; Watson, John; Woodward, Mark; Zoungas, Sophia; Mancia, Giuseppe; Poulter, Neil; Central Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; Northern Clinical School: Medicine; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthEffects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trial, PLoS One, vol.8, 2, 2013,pp 1-7
2015Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled TrialFulcher, Greg; Neal, Bruce; Perkovic, Vlado; Capuano, George; de Zeeuw, Dick; Desai, Mehul; Mahaffey, Kenneth W; Matthews, David. R.; Meininger, G; Rosenstock, Julio; Shaw, Wayne; Vercruysse, Frank; Weiss, Robert; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthEfficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial, Diabetes Therapy, vol.6, 3, 2015,pp 289-302